钱塘江畔聚智赋能 AI+平台助推生物医药“加速跑”

Core Insights - Zhejiang Province is leveraging the "AI+" initiative to establish Hangzhou as a hub for AI innovation, with Qiantang New District focusing on AI in pharmaceuticals, embodied intelligence, and high-end chips [1][2] - The integration of AI in drug development is transforming traditional pharmaceutical processes, significantly reducing the time and cost associated with drug discovery [1][3] Industry Development - Qiantang New District is home to key research platforms like Zhejiang University’s Intelligent Innovation Drug Research Institute and the Chinese Academy of Sciences Hangzhou Medical Institute, which are addressing bottlenecks in new drug development using AI [2][3] - The district has developed a comprehensive AI-driven drug research system that enhances efficiency by discovering new clinical targets and optimizing drug design [3][4] Collaborative Efforts - Over 200 technical collaborations have occurred in Qiantang, with the Zhejiang University institute partnering with 15 companies to establish joint research centers and incubate new pharmaceutical firms [3][4] - The establishment of the "Hangzhou Nucleic Acid Drug Valley" has attracted over 30 leading companies, creating a complete cycle from basic research to industrialization [4] AI Integration - Qiantang has initiated 15 AI model projects and established 18 provincial-level AI research platforms, attracting over 110 AI companies [5][6] - AI technologies are being applied across the pharmaceutical industry, enhancing drug development, manufacturing, and diagnostic processes, thereby driving precision medicine and smart clinical practices [6] Future Outlook - Qiantang aims to build a nationally influential biopharmaceutical innovation hub by continuously enhancing platform foundations and expanding industry scale through open and innovative strategies [6]